Try our Advanced Search for more refined results

Amgen Inc. et al v. Hospira, Inc.

  1. July 07, 2016

    Hospira, Amgen Duel Over Biosimilar Ruling's Impact

    Hospira and Amgen are crossing swords in Delaware federal court over a new Federal Circuit ruling on the obligations of biosimilars makers, debating whether it means that companies can enforce a key provision in the Biologics Price Competition and Innovation Act.

  2. February 16, 2016

    Amgen Fights Dismissal Bid In Del. Biosimilar Drug Case

    A Pfizer Inc. subsidiary urged a federal judge in Delaware on Tuesday to toss a claim that it failed to share full information about a potential new product similar to an Amgen Inc. anemia drug, arguing that Congress never authorized private actions to enforce the disclosures.

  3. October 14, 2015

    Amgen Can't Enforce Biosimilar Law, Hospira Says

    Amgen Inc. can't enforce a federal law that calls for biosimilar makers to share manufacturing information and provide advance notice of sales, Hospira Inc. told a Delaware federal judge on Tuesday.

  4. September 21, 2015

    Amgen Sues Hospira Over Biosimilar Info, Notice

    Amgen Inc. on Friday sued Hospira Inc. in Delaware federal court for allegedly violating information-sharing and advance-notice provisions of the Biologics Price Competition and Innovation Act, adding to a flurry of litigation that will decide how quickly biosimilars get to market.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!